Stephens & Co. Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $3

Stephens & Co. analyst Mason Carrico maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and lowers the price target from $5 to $3.